Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer

被引:184
作者
Kim, Eun Young [1 ]
Kim, Young Saing [2 ]
Park, Inkeun [2 ]
Ahn, Hee Kyung [2 ]
Cho, Eun Kyung [2 ]
Jeong, Yu Mi [1 ]
机构
[1] Gachon Univ, Gil Hosp, Dept Radiol, Inchon 405760, South Korea
[2] Gachon Univ, Gil Hosp, Dept Internal Med, Div Hematol & Oncol, Inchon 405760, South Korea
关键词
Sarcopenia; Skeletal muscle; Prognosis; Small-cell lung cancer; Tomography; X-ray computed; BODY-COMPOSITION; PREVALENCE; CHEMOTHERAPY; OBESITY; INDEX;
D O I
10.1097/JTO.0000000000000690
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The primary objective of this study was to determine the prognostic significance of computed tomography (CT)-determined sarcopenia in small-cell lung cancer (SCLC) patients. Methods: This retrospective study consisted of a total of 149 consecutive SCLC patients. The cross-sectional area of muscle at the level of the third lumbar vertebra (L3) was measured using baseline CT images. Sarcopenia was defined as a L3 muscle index of less than 55 cm(2)/m(2) for men and of less than 39 cm(2)/m(2) for women as proposed by international consensus of cancer cachexia. In addition, Korean-specific cutoffs for sarcopenia was also applied (49 cm(2)/m(2) for men and 31 cm(2)/m(2) for women). Overall survival (OS) and clinical characteristics of patients with or without sarcopenia were compared. Results: Mean patient age was 68.6 9.5 years. Most were male (85.3%) and 67.8% had extensive disease at time of diagnosis. Sarcopenia was present in 118 patients (79.2%) and was significantly related to an advanced age (p = 0.028), male sex (p < 0.001), lower body mass index (p < 0.001), and poor performance status (p = 0.049). Sarcopenic patients had shorter OS than nonsarcopenic patients (median: 8.6 months versus 16.8 months; p = 0.031). Multivariable analysis revealed that sarcopenia was an independent prognostic factor of poor survival (hazards ratio: 1.68; 95% confidence interval: 1.04-2.72; p = 0.034), along with extensive stage (p < 0.001), supportive care only (p < 0.001), and an elevated lactate dehydrogenase level (p = 0.020). Using Korean sarcopenia cutoffs, sarcopenic patients were also found to have poorer OS than nonsarcopenic patients, however, the survival difference was not statistically significant (median: 8.4 months versus 12.7 months; p = 0.144 by the log-rank test). Conclusions: Sarcopenia as determined by CT could be used to predict prognosis in patients with SCLC. Optimum reference values to predict cancer-specific outcomes should be tailored by further studies.
引用
收藏
页码:1795 / 1799
页数:5
相关论文
共 23 条
  • [1] Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis
    Baracos, Vickie E.
    Reiman, Tony
    Mourtzakis, Marina
    Gioulbasanis, Ioannis
    Antoun, Sami
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2010, 91 (04) : 1133S - 1137S
  • [2] Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies
    Barba, C
    Cavalli-Sforza, T
    Cutter, J
    Darnton-Hill, I
    Deurenberg, P
    Deurenberg-Yap, M
    Gill, T
    James, P
    Ko, G
    Miu, AH
    Kosulwat, V
    Kumanyika, S
    Kurpad, A
    Mascie-Taylor, N
    Moon, HK
    Nishida, C
    Noor, MI
    Reddy, KS
    Rush, E
    Schultz, JT
    Seidell, J
    Stevens, J
    Swinburn, B
    Tan, K
    Weisell, R
    Wu, ZS
    Yajnik, CS
    Yoshiike, N
    Zimmet, P
    [J]. LANCET, 2004, 363 (9403) : 157 - 163
  • [3] Baumgartner RN, 2000, ANN NY ACAD SCI, V904, P437
  • [4] The assessment and impact of sarcopenia in lung cancer: a systematic literature review
    Collins, Jemima
    Noble, Simon
    Chester, John
    Coles, Bernadette
    Byrne, Anthony
    [J]. BMJ OPEN, 2014, 4 (01):
  • [5] Definition and classification of cancer cachexia: an international consensus
    Fearon, Kenneth
    Strasser, Florian
    Anker, Stefan D.
    Bosaeus, Ingvar
    Bruera, Eduardo
    Fainsinger, Robin L.
    Jatoi, Aminah
    Loprinzi, Charles
    MacDonald, Neil
    Mantovani, Giovanni
    Davis, Mellar
    Muscaritoli, Maurizio
    Ottery, Faith
    Radbruch, Lukas
    Ravasco, Paula
    Walsh, Declan
    Wilcock, Andrew
    Kaasa, Stein
    Baracos, Vickie E.
    [J]. LANCET ONCOLOGY, 2011, 12 (05) : 489 - 495
  • [6] Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Frueh, M.
    De Ruysscher, D.
    Popat, S.
    Crino, L.
    Peters, S.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 : 99 - 105
  • [7] Sarcopenia as a Prognostic Biomarker of Advanced Urothelial Carcinoma
    Fukushima, Hiroshi
    Yokoyama, Minato
    Nakanishi, Yasukazu
    Tobisu, Ken-ichi
    Koga, Fumitaka
    [J]. PLOS ONE, 2015, 10 (01):
  • [8] Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
    Govindan, Ramaswamy
    Page, Nathan
    Morgensztern, Daniel
    Read, William
    Tierney, Ryan
    Vlahiotis, Anna
    Spitznagel, Edward L.
    Piccirillo, Jay
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) : 4539 - 4544
  • [9] Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma
    Harimoto, N.
    Shirabe, K.
    Yamashita, Y. -I.
    Ikegami, T.
    Yoshizumi, T.
    Soejima, Y.
    Ikeda, T.
    Maehara, Y.
    Nishie, A.
    Yamanaka, T.
    [J]. BRITISH JOURNAL OF SURGERY, 2013, 100 (11) : 1523 - 1530
  • [10] Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
    Huillard, O.
    Mir, O.
    Peyromaure, M.
    Tlemsani, C.
    Giroux, J.
    Boudou-Rouquette, P.
    Ropert, S.
    Delongchamps, N. Barry
    Zerbib, M.
    Goldwasser, F.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1034 - 1041